The Readout Loud
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
226
Episode 173: Biden's drug pricing plan, Wall St...
First, STAT Washington correspondent Nicholas Flo…
30 min
227
Episode 172: The mRNA gold rush, Delta's alarmi...
First, we dive into the potential of mRNA, a tech…
33 min
228
Episode 171: The quest for a Covid pill, a micr...
First, we discuss the CDC's about-face on mask we…
34 min
229
Episode 170: Céline Gounder on breakthrough inf...
First, Céline Gounder of NYU’s Grossman School of…
32 min
230
Episode 169: Dan Diamond on covering Biden, plu...
First, we'll talk about the future of the FDA, wh…
30 min
231
Episode 168: Aduhelm's latest twist, & how Covi...
First, we discuss the latest twists following the…
31 min
232
Episode 167: George Yancopoulos on biotech in 2...
First we talk to George Yancopoulos, head scienti…
43 min
233
Episode 166: FDA inner workings, GSK's foggy fu...
First, we sift through the week's news, with a ma…
37 min
234
Episode 165: Paul Offit on the Covid vaccine bo...
First, we sift through the week's news, with some…
34 min
235
Episode 164: Every angle on the FDA's polarizin...
We're devoting this entire episode to the FDA's p…
40 min
236
Episode 163: Marilynn Marchione on covering the...
First, we discuss why it's so hard to predict FDA…
28 min
237
Episode 162: Scott Gottlieb on Covid and grilli...
STAT's Andrew Joseph joins us to talk about the t…
32 min
238
Episode 161: Biotech meme stocks, the lessons o...
First, we discuss Ginkgo Bioworks, the multibilli…
38 min
239
Episode 160: Global Covid-19 failures, a sluggi...
Can we prevent the next Covid-19? Has the CDC bec…
29 min
240
Episode 159: Thomas Bollyky on patent waivers, ...
First, Moderna and Pfizer are poised to make bill…
33 min
241
Episode 158: Angela Rasmussen on Russia's vacci...
First, STAT Washington correspondent Rachel Cohrs…
28 min
242
Episode 157: Mercedes Carnethon on outdoor mask...
First, Northwestern University epidemiologist Mer…
33 min
243
Episode 156: J&J's vaccine pause, talking about...
How do you describe a one-in-a-million risk? What…
30 min
244
Episode 155: AstraZeneca's vaccine woes, compas...
What's next for AstraZeneca? Are there any right …
30 min
245
Episode 154: Eleanor Fox on Illumina’s FTC head...
First, STAT’s Mario Aguilar joins us to discuss a…
33 min
246
Episode 153: AstraZeneca and the very good, the...
We're devoting this week's episode to the week of…
27 min
247
Episode 152: Alison Buttenheim on Europe's vacc...
First we unpack the crisis of confidence facing A…
29 min
248
Episode 151: Natasha Loder on Covid vaccines, t...
We're joined by Natasha Loder, the health policy …
29 min
249
Episode 150: Ashish Jha on Covid-19 optimism, p...
We discuss Merck's decision to help Johnson & Joh…
31 min
250
Episode 149: Nancy Goodman on Covid vaccines fo...
First, pediatric cancer advocate Nancy Goodman jo…
31 min